Clarius Group LLC’s iShares Biotechnology ETF IBB Stock Holding History

Clarius Group LLC’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,700	Closed	-$638K	–	494
2023 Q4	$638K	Buy	+4,700	New	+$573K	0.05%	196

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Clarius Group LLC's IBB Position: Q1 2024 in Review

Clarius Group LLC sold out of iShares Biotechnology ETF (IBB) in Q1 2024, closing a stake of 4,700 shares — an estimated $638K sold.

Clarius Group LLC first reported a position in IBB in Q4 2023 and held it in 1 quarter. The position peaked at $638K in Q4 2023. 899 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

Clarius Group LLC reported no remaining iShares Biotechnology ETF position as of Q1 2024 after selling out during the quarter.
Clarius Group LLC sold 4,700 iShares Biotechnology ETF shares in Q1 2024, an estimated $638K.
Clarius Group LLC first reported a position in iShares Biotechnology ETF in Q4 2023 and held it in 1 quarter.
Clarius Group LLC's iShares Biotechnology ETF position peaked at $638K in Q4 2023.
899 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Clarius Group LLC's 13F filing for Q1 2024, filed 17 Apr 2024.